Terms: = Uterine cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
13 results:
1. Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.
Takao T; Masuda H; Kajitani T; Miki F; Miyazaki K; Yoshimasa Y; Katakura S; Tomisato S; Uchida S; Uchida H; Tanaka M; Maruyama T
Stem Cell Res Ther; 2022 Jun; 13(1):225. PubMed ID: 35659728
[TBL] [Abstract] [Full Text] [Related]
2. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y; Huang J; Ivan C; Sun Y; Ma S; Mangala LS; Fellman BM; Urbauer DL; Jennings NB; Ram P; Coleman RL; Hu W; Sood AK
Gynecol Oncol; 2021 Oct; 163(1):181-190. PubMed ID: 34391578
[TBL] [Abstract] [Full Text] [Related]
3. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
Coleman RL; Hu W; Soliman P; Nick A; Ramirez PT; Westin SN; Garcia ME; Zhu Z; Palancia J; Fellman BM; Yuan Y; Ram P; Bischoff F; Schmeler K; Bodurka D; Meyer LA; Sood AK
Gynecol Oncol; 2021 Apr; 161(1):104-112. PubMed ID: 33551196
[TBL] [Abstract] [Full Text] [Related]
4. RCE‑4, a potential anti‑cervical cancer drug isolated from Reineckia carnea, induces autophagy via the dual blockade of PI3K and ERK pathways in cervical cancer CaSki cells.
Xiang W; Zhang RJ; Jin GL; Tian L; Cheng F; Wang JZ; Xing XF; Xi W; Tang SJ; Chen JF
Int J Mol Med; 2020 Jan; 45(1):245-254. PubMed ID: 31746346
[TBL] [Abstract] [Full Text] [Related]
5. CircAGFG1 promotes cervical cancer progression via miR-370-3p/raf1 signaling.
Wu F; Zhou J
BMC Cancer; 2019 Nov; 19(1):1067. PubMed ID: 31703640
[TBL] [Abstract] [Full Text] [Related]
6. Bag-1L is a stress-withstand molecule prevents the downregulation of Mcl-1 and c-raf under control of heat shock proteins in cisplatin treated HeLa cervix cancer cells.
Ozfiliz P; Arisan ED; Coker-Gurkan A; Obakan P; Eralp TN; Dinler-Doganay G; Palavan-Unsal N
Asian Pac J Cancer Prev; 2014; 15(11):4475-82. PubMed ID: 24969872
[TBL] [Abstract] [Full Text] [Related]
7. Cross-talk between EphA2 and BRaf/craf is a key determinant of response to Dasatinib.
Huang J; Hu W; Bottsford-Miller J; Liu T; Han HD; Zand B; Pradeep S; Roh JW; Thanapprapasr D; Dalton HJ; Pecot CV; Rupaimoole R; Lu C; Fellman B; Urbauer D; Kang Y; Jennings NB; Huang L; Deavers MT; Broaddus R; Coleman RL; Sood AK
Clin Cancer Res; 2014 Apr; 20(7):1846-55. PubMed ID: 24486585
[TBL] [Abstract] [Full Text] [Related]
8. Anti-proliferative and pro-apoptotic effects of 3,3'-diindolylmethane in human cervical cancer cells.
Zhu J; Li Y; Guan C; Chen Z
Oncol Rep; 2012 Sep; 28(3):1063-8. PubMed ID: 22736073
[TBL] [Abstract] [Full Text] [Related]
9. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract] [Full Text] [Related]
10. Differential impact of raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract] [Full Text] [Related]
11. raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
Britten RA; Perdue S; Eshpeter A; Merriam D
Oncol Rep; 2000; 7(4):821-5. PubMed ID: 10854551
[TBL] [Abstract] [Full Text] [Related]
12. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens.
Britten RA; Perdue S; Opoku J; Craighead P
Radiother Oncol; 1998 Sep; 48(3):329-34. PubMed ID: 9925253
[TBL] [Abstract] [Full Text] [Related]
13. High raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity.
Rasouli-Nia A; Liu D; Perdue S; Britten RA
Clin Cancer Res; 1998 May; 4(5):1111-6. PubMed ID: 9607567
[TBL] [Abstract] [Full Text] [Related]
